Cervical Cancer Diagnostic Top Companies
The global cervical cancer diagnostic market size is calculated at US$ 5.08 billion in 2024, grew to US$ 5.37 billion in 2025, and is projected to reach around US$ 8.87 billion by 2034. The market is expanding at a CAGR of 5.74% between 2024 and 2034.
Cervical Cancer Diagnostic Top Key Players:
- Abbott Laboratories
- Aptamer Group, plc
- Becton, Dickinson and Company
- Danaher Corporation
- F. Hoffman-La Roche Ltd.
- Guided Therapeutics, Inc.
- Healthians
- Hologic, Inc.
- MobileODT Ltd
- Novartis AG
- Quest Diagnostics
- Roche Diagnostics
- Timser Group
Latest Announcements by Industry Leaders
Matt Sause, CEO of Roche Diagnostics commented on the launch of its new HPV self-testing kit that the kit offers an accessible screening solution. He said that the WHO’s goal of eliminating cervical cancer can be achieved through vaccinations, innovative diagnostic tools, and screening programs. Their self-collection solution can reduce barriers and provide access to HPV screening.
Recent Developments in the Cervical Cancer Diagnostic Market
- In July 2024, researchers from the Waseda University, Kanazawa Medical University, and German Cancer Research Center developed a non-invasive alternative method to detect high-risk HPV16 E7 oncoproteins in urine using ELISA.
- In May 2024, Aptamer Group, plc announced a collaboration with Timser Group with a deal value of up to £465,000. The collaboration was made to develop the world’s first blood test for cervical cancer through Timser’s patented cervical cancer biomarker panel.
If you have any questions, please feel free to contact us at
